Hansa Medical Interim report April – June 2016
July 21, 2016 02:30 ET
|
Hansa Medical AB
Continued positive development of IdeS in clinical studies
Second quarter in brief
Business highlights
›› US Food and Drug Administration (FDA) cleared Hansa Medical’s IND application
for a study...
Hansa Medical delårsrapport april – juni 2016
July 21, 2016 02:30 ET
|
Hansa Medical AB
Fortsatt positiv utveckling av IdeS
Andra kvartalet i korthet
Verksamheten i sammandrag
›› FDA gav Hansa Medical klartecken att påbörja kliniska studier med IdeS inom
njurtransplantation
›› Alla...
Hansa Medical förvärvar rättigheter till immunterapi baserad på antikroppsmodulerande enzymer för behandling av cancer
July 19, 2016 07:00 ET
|
Hansa Medical AB
Hansa Medical AB (publ) har förvärvat Immago Biosystems Ltd, en avknoppning från
University of Oxford, med inriktning på förstärkning av antikroppsbaserade
cancerbehandlingar med hjälp av...
Hansa Medical acquires rights to cancer immunotherapy using antibody-modulating enzymes
July 19, 2016 07:00 ET
|
Hansa Medical AB
Hansa Medical AB (publ) today announced the acquisition of UK based Immago
Biosystems Ltd, a University of Oxford-spinout focused on the enhancement of
antibody based cancer therapies using...
Hansa Medical initiates pivotal multicenter study in the US with IdeS for treatment of refractory highly sensitized kidney patients
July 19, 2016 02:30 ET
|
Hansa Medical AB
Hansa Medical AB (publ) today announced that the company sponsored pivotal
multicenter study in the US with IdeS in refractory highly sensitized patients
is open for recruitment.
The single arm Phase...
Hansa Medical initierar en registreringsgrundande amerikansk multicenterstudie med IdeS i behandlingsresistenta högsensitiserade njurpatienter
July 19, 2016 02:30 ET
|
Hansa Medical AB
Hansa Medical AB (publ) meddelade idag att rekrytering av patienter till en
registreringsgrundande amerikansk multicenterstudie med bolagets
läkemedelskandidat IdeS i behandlingsresistenta...
Successful desensitization with IdeS in all recruited patients in ongoing US Phase II study
June 15, 2016 02:30 ET
|
Hansa Medical AB
Hansa Medical AB (publ) today announced that additional data from the ongoing US
Phase II study with IdeS in kidney transplantation was presented at the 2016
American Transplant Congress (ATC) in...
Framgångsrik desensitisering med IdeS i samtliga inkluderade patienter i pågående amerikansk fas II-studie
June 15, 2016 02:30 ET
|
Hansa Medical AB
Hansa Medical AB (publ) meddelade idag att ytterligare data från den pågående
amerikanska fas II-studien med IdeS i njurtransplantation presenterades vid 2016
American Transplant Congress (ATC) i...
Initial results from the ongoing Swedish Phase II study with IdeS in sensitized kidney transplant patients will be presented at TTS 2016
May 31, 2016 02:30 ET
|
Hansa Medical AB
Dr. Tomas Lorant, principal investigator, will present data from the ongoing
Swedish Phase II study with IdeS in sensitized kidney transplant patients at the
26thInternational Congress of the...
Inledande resultat från den pågående svenska fas II-studien med IdeS i sensitiserade transplantationspatienter presenteras vid TTS 2016
May 31, 2016 02:30 ET
|
Hansa Medical AB
Dr. Tomas Lorant, ansvarig prövare, kommer att presentera data från den pågående
svenska fas II-studien med IdeS i sensitiserade njurtransplantationspatienter
vid The 26th International Congress of...